NYSE · Financial Statements

USANA Health Sciences, Inc. (USNA) Financial Statements

$13.96 NYSE: USNA Market Cap $257.93M

USANA Health Sciences, Inc. most recently reported annual revenue of $925.0M, net profit of $11.0M. Revenue declined at an average annual rate of 4.0% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

USANA Health Sciences, Inc.: Revenue fell from $1.0B in 2016 to $925.0M in 2025, a change of -8.1% over 9 years; net profit was positive in all 10 reported years; operating margin moved from 13.8% to 5.5%, a shift of -8.3 percentage points; the most recent year shows net profit of $11.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$1.0B$1.0B$1.2B$1.1B$1.1B$1.2B$999.0M$921.0M$855.0M$925.0M
Operating Expenses$867.0M$915.0M$1.0B$915.0M$958.0M$1.0B$891.0M$828.0M$788.0M$874.0M
Operating Profit$139.0M$133.0M$188.0M$146.0M$176.0M$170.0M$108.0M$93.0M$66.0M$51.0M
Operating Margin13.8%12.7%15.8%13.8%15.6%14.3%10.8%10.1%7.8%5.5%
Other Income$0$2.0M$3.0M$4.0M$1.0M$0$1.0M$9.0M$10.0M$-9.0M
Interest$0$0$0$0$1.0M$0$0$0$0$1.0M
Depreciation$13.0M$16.0M$17.0M$23.0M$23.0M$22.0M$21.0M$20.0M$22.0M$40.0M
Profit Before Tax$139.0M$135.0M$192.0M$150.0M$178.0M$171.0M$109.0M$102.0M$76.0M$42.0M
Tax$27.8M$53.5M$34.1M$33.2M$29.9M$31.7M$36.1M$37.7M$44.9M$72.4M
Net Profit$100.0M$63.0M$126.0M$101.0M$125.0M$117.0M$69.0M$64.0M$42.0M$11.0M
EPS$3.99$2.53$5.12$4.41$5.86$5.73$3.59$3.30$2.19$0.58
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricJun '23Sep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Mar '26Jun '26
Revenue$248.0M$213.0M$221.0M$228.0M$213.0M$200.0M$214.0M$250.0M$236.0M$214.0M$226.0M$250.0M
Operating Expenses$222.0M$196.0M$197.0M$203.0M$195.0M$185.0M$205.0M$234.0M$219.0M$212.0M$209.0M$236.0M
Operating Profit$27.0M$18.0M$24.0M$25.0M$18.0M$16.0M$8.0M$16.0M$17.0M$1.0M$17.0M$14.0M
Operating Margin10.8%8.3%10.9%10.8%8.4%7.8%3.8%6.3%7.1%0.6%7.6%5.5%
Interest$0$0$0$0$0$0$0$0$0$0$0$0
Profit Before Tax$29.0M$21.0M$27.0M$27.0M$20.0M$19.0M$10.0M$17.0M$19.0M$2.0M$4.0M$15.0M
Tax$35.5M$44.7M$37.0M$39.0M$48.4M$43.0M$57.0M$44.5M$44.5M$471.4M$138.2M$55.0M
Net Profit$18.0M$11.0M$17.0M$17.0M$10.0M$11.0M$4.0M$9.0M$10.0M$-7.0M$-2.0M$8.0M
EPS$0.95$0.59$0.87$0.86$0.54$0.56$0.23$0.49$0.52$-0.36$-0.10$0.41

Over the 10 years reported for USANA Health Sciences, Inc., cash stood at $158.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 2.23 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$471.0M$519.0M$554.0M$517.0M$641.0M$578.0M$597.0M$633.0M$748.0M$743.0M
Current Assets$278.0M$340.0M$392.0M$328.0M$423.0M$363.0M$381.0M$418.0M$279.0M$288.0M
Cash$176.0M$247.0M$214.0M$235.0M$313.0M$240.0M$288.0M$330.0M$182.0M$158.0M
Inventory$65.0M$63.0M$82.0M$69.0M$90.0M$98.0M$67.0M$61.0M$70.0M$103.0M
Receivables$17.0M$13.0M$14.0M$9.0M$7.0M$7.0M$7.0M$7.0M$8.0M$0
Fixed Assets$101.0M$103.0M$92.0M$126.0M$128.0M$126.0M$118.0M$100.0M$95.0M$112.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$10.0M$10.0M$66.0M$3.0M$3.0M$24.0M$3.0M$3.0M$3.0M$20.0M
Other Assets$17.0M$17.0M$17.0M$17.0M$17.0M$18.0M$17.0M$17.0M$144.0M$138.0M
Total Liabilities$145.0M$156.0M$163.0M$165.0M$199.0M$183.0M$162.0M$136.0M$162.0M$157.0M
Current Liabilities$138.0M$141.0M$149.0M$136.0M$168.0M$161.0M$144.0M$119.0M$140.0M$129.0M
Borrowings$0$0$0$26.0M$21.0M$17.0M$14.0M$13.0M$39.0M$14.0M
Other Liabilities$145.0M$156.0M$163.0M$140.0M$178.0M$165.0M$148.0M$122.0M$123.0M$143.0M
Equity$0$0$0$0$0$0$0$0$0$0
Reserves$325.0M$363.0M$391.0M$352.0M$442.0M$395.0M$434.0M$497.0M$532.0M$533.0M

For USANA Health Sciences, Inc., operating cash flow was positive in 10 of 10 reported years; free cash flow in the latest year was $9.0M; free cash flow was positive in 10 of 10 years; financing activities used $32.0M in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow$137.0M$124.0M$152.0M$127.0M$160.0M$121.0M$104.0M$71.0M$61.0M$22.0M
Investing Cash Flow$-65.0M$-26.0M$-80.0M$31.0M$-49.0M$-27.0M$-23.0M$-26.0M$-223.0M$-24.0M
Financing Cash Flow$-65.0M$-50.0M$-105.0M$-150.0M$-59.0M$-181.0M$-30.0M$-15.0M$-13.0M$-32.0M
Net Cash Flow$33.0M$71.0M$-33.0M$20.0M$78.0M$-72.0M$48.0M$42.0M$-149.0M$-23.0M
Free Cash Flow$104.0M$111.0M$141.0M$110.0M$145.0M$108.0M$94.0M$56.0M$51.0M$9.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.07
EV / EBITDA3.22
FCF Yield5.82%
Quick Ratio1.84
Interest Coverage29.98
Return 1Y-40.95%
Return 3Y-67.20%
Return 5Y-77.66%

USANA Health Sciences, Inc. (USNA) financials — frequently asked questions

What is USANA Health Sciences, Inc.'s annual revenue?

USANA Health Sciences, Inc. (USNA) reported annual revenue of $925.0M in its most recent fiscal year.

What is USANA Health Sciences, Inc.'s net profit?

USANA Health Sciences, Inc. (USNA) reported net profit of $11.0M in its most recent fiscal year.

What is USNA EV/EBITDA?

USANA Health Sciences, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 3.22.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Consumer Defensive StocksLow P/E Consumer Defensive StocksHigh Net Margin Consumer Defensive StocksDividend Consumer Defensive StocksLow Debt Consumer Defensive StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNYSE High ROE StocksAll stock screens
USNA Overview USNA Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.